RESMED INC
Ticker: RMDHealthcareSurgical & Medical InstrumentsS&P 500The business
ResMed Inc. (NYSE: RMD) is a global leader in digital health and cloud-connected medical devices headquartered in the United States with operations across more than 140 countries. The company's website is www.resmed.com.
ResMed designs innovative technology to empower people to live healthier lives through artificial intelligence-powered digital health solutions, cloud-connected devices, and intelligent software focused on making home healthcare more personalized, accessible, and effective. The company operates through two reportable segments: Sleep and Breathing Health, which accounts for approximately 88 percent of net revenues, and Residential Care Software, which represents approximately 12 percent of net revenues.
The Sleep and Breathing Health segment encompasses a comprehensive portfolio addressing obstructive sleep apnea, central sleep apnea, chronic obstructive pulmonary disease, obesity hypoventilation syndrome, and neuromuscular diseases. ResMed's device portfolio includes CPAP, APAP, bilevel, and ventilation systems marketed under brands such as AirSense, AirCurve, AirMini, Astral, and Stellar. The company also manufactures mask systems, diagnostic products, and accessories, which together represent approximately 37 percent of net revenues, while devices account for approximately 51 percent. Connected solutions including the AirView cloud-based monitoring platform and myAir patient engagement application enable remote patient management and therapy adherence tracking across an installed base exceeding 35 million cloud-connected devices.
The Residential Care Software segment provides cloud-based solutions to healthcare providers through brands including Brightree, MatrixCare, HEALTHCAREfirst, and MEDIFOX DAN, supporting home medical equipment providers, home health and hospice agencies, skilled nursing facilities, and senior living communities. In June 2026, ResMed acquired Noctrix Health, expanding its clinical sleep health portfolio into restless legs syndrome treatment. The company also operates VirtuOx, an independent diagnostic testing facility acquired in 2025 that provides home-based and remote testing services.
ResMed employs approximately 11,370 people and serves patients globally through wholly owned subsidiaries and independent distributors. The company was founded in 1989 and completed its initial public offering in 1995, subsequently listing on the New York Stock Exchange in 1999.
- Sector
- Healthcare
- Industry
- Surgical & Medical Instruments
- HQ
- SAN DIEGO, CA
- FY end
- 06-30
- CIK
- 943819
- SIC
- 3841
Ownership
Who holds RESMED INC — across funds, superinvestors and bonds · N-PORT 2026Q2 · 13F 2026-06-30
Top fund holders
| Fund | % of fund | Value |
|---|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND VTI · VANGUARD INDEX FUNDS | 0.04% | $897.48M |
| VANGUARD 500 INDEX FUND VOO · VANGUARD INDEX FUNDS | 0.04% | $732.38M |
| VANGUARD MID-CAP INDEX FUND VO · VANGUARD INDEX FUNDS | 0.27% | $612.51M |
| iShares Core S&P 500 ETF IVV · iShares Trust | 0.04% | $388.76M |
| VANGUARD GROWTH INDEX FUND VUG · VANGUARD INDEX FUNDS | 0.10% | $363.65M |
Superinvestors in RESMED INC
Share of each manager's reported 13F portfolio.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Go deeper in your own AI
15 years of statements, narrative and filings — queryable over MCP.
Professionals can also use the built-in AI chat (subscription + your own Anthropic key).
15 years of RESMED INC's financials
Income statement, balance sheet and cash flow across 15 years, every filing with its disclosures, and each number traceable to the filing it came from — free with an account, no card required.
Sign in free